The preterm birth prevention and management market is set to experience remarkable growth over the next decade. Valued at an estimated USD 1.70 billion in 2024, the market is projected to exceed USD 4.49 billion by 2034, registering an impressive Compound Annual Growth Rate (CAGR) of 10.2%.
The increasing focus on preventing and managing preterm births across both developed and developing countries is driving this growth. With the adoption of advanced therapeutics and management strategies, healthcare providers are better equipped to address the challenges associated with preterm births. These efforts are crucial in improving neonatal outcomes and reducing the long-term health complications associated with preterm births.
The market’s expansion is also fueled by rising awareness, increased healthcare investments, and ongoing advancements in medical technologies. The growing emphasis on research and development in this field further enhances the potential for innovative solutions to prevent and manage preterm births effectively.
Get your PDF Sample Report:
https://www.futuremarketinsights.com/reports/sample/rep-gb-6457
The market’s expansion is fueled by several factors, including increased research and development activities, technological advancements in prenatal care, and supportive government initiatives. Furthermore, the integration of advanced diagnostic tools and personalized medicine approaches are revolutionizing the prevention and management of preterm births, offering tailored solutions to meet the unique needs of expectant mothers.
As the global preterm birth prevention and management market continues its upward trajectory, industry stakeholders are well-positioned to capitalize on emerging opportunities. By leveraging advancements in medical science, enhancing accessibility to therapeutic solutions, and fostering awareness, the industry can make significant strides in combating preterm birth and promoting maternal and child health.
Key Takeaways of the Study
- Development of higher complexity specific portfolios and consistent focus on areas of strength while working pipelines are the cornerstone for success in the preterm birth prevention market space.
- Ensuring preterm interventions and research given proportional focus, so funding is aligned with health burden to curb the mortality rate
- Makena, with various approvals for the treatment of preterm birth in potential female patient pool, contributed to the dominance of the progesterone therapy segment by therapy type in 2018 and continue to do so during the forecast period.
- Highly effective therapies with cost advantage over are expected to generate significant revenue in the long run.
- Majority of the global preterm birth cases have not been directed towards preterm diagnostic leading to higher mortality rates and complications
- Sale of Hydroxyprogesterone over antihypertensive drugs such as Nifedipine, and labetalol in the global preterm birth prevention and management market has increased drastically owing to quicker onset of action and higher efficacy.
The demand from high preterm birth rate countries, development of new drug entity, loss of exclusivity in hydroxyprogesterone, and growth strategies based on tie up with distribution channel partners are projected to offer new growth opportunities for the preterm birth prevention and management market.
Customization Available:
https://www.futuremarketinsights.com/customization-available/REP-GB-6457
Launch of Cost-effective Therapies Bodes Well for Market
New revenue opportunities in developed economies, and orphan drug designation by FDA are contributing significantly towards the launch of cost-effective therapies. A few other factors assisting the growth of preterm birth prevention and management market include adoption of preterm diagnostic tests and the economic burden of premature birth on the system.
Frequent drug shortages and unavailability of life-saving formulations in many parts of the country, growing initiatives by government and manufacturers for supply of life-saving preterm birth drugs, particularly in low income and developing countries, are driving the market growth.
Strategic Acquisitions by Key Players to Widen Regional Presence
The leading players in the preterm birth prevention and management market such as AMAG Pharmaceuticals, Pfizer Inc., and Mylan, are concentrating on organic revenue growth and commercial expansions by mergers and distribution agreements and capturing the untapped potential of the preterm birth prevention and management market.
- In 2022, AMAG Pharmaceuticals, Inc. a largest preterm birth prevention and management drug manufacturer announced the completion of acquisition of Perosphere Pharmaceuticals Inc., a private biopharmaceutical firm. With the acquisition, AMAG received ciraparantag to its development portfolio. This acquisition further strengthened AMAG Pharmaceuticals hold of preterm birth prevention and management business with addition of heparin therapy
- AMAG acquired the global rights to R&D and marketing of digoxin immune Fab, a drug used to treat severe preeclampsia in pregnant women from Velo Bio, LLC.
More Valuable Insights on Preterm birth prevention and management Market
Future Market Insights brings the comprehensive research report on forecasted revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the segments from 2014 to 2029. The global preterm birth prevention and management market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader.
Preterm Birth Prevention and Management Market by Category
By Therapy Type:
- Progesterone Therapy
- Corticosteroid Therapy
- Tocolytics Therapy
- Antihypertensive Therapy
- Magnesium Sulfate Therapy
- Heparin Prophylaxis Therapy
- Low-Dose Aspirin Therapy
- Antibiotics Therapy
By Route of Administration:
- Oral
- Parenteral
- Vaginal
By Patient Type:
- Prior Spontaneous PTB
- Preeclampsia
- Short Cervix
- Chronic Hypertension
- Insulin-dependent
- Twins
- Antiphospholipid Antibody Syndrome
- Others
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Drug Stores
- Mail Order Pharmacies
By Region:
- North America
- Europe
- Latin America
- South Asia
- East Asia
- Oceania
- Middle East and Africa
Get Full Market Analysis Now: Purchase The Report:
https://www.futuremarketinsights.com/checkout/6457
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
